share_log

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3

富國銀行維持Adaptimmune Therapeutics的同等權重,將目標價提高至3美元
Benzinga Real-time News ·  2022/11/14 07:36

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Equal-Weight and raises the price target from $1.5 to $3.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論